Clearmind Secures U.S. Patent for Binge Behavior Regulators
Event summary
- Clearmind Medicine granted U.S. Patent No. 12,350,242 for 'BINGE BEHAVIOR REGULATORS' on June 18, 2026.
- Patent covers MEAI (5-methoxy-2-aminoindane) for regulating binge behaviors like excessive drinking, eating, and gambling.
- Clearmind's global patent portfolio now includes 32 granted patents across 19 patent families.
- CEO Dr. Adi Zuloff-Shani highlights the patent's role in advancing clinical programs for alcohol use disorder.
The big picture
Clearmind's latest U.S. patent strengthens its position in the psychedelic therapeutics space, particularly for binge-related disorders. The company's focus on non-hallucinogenic, neuroplastogen-derived treatments aligns with growing industry interest in addressing under-treated mental health conditions. With 32 granted patents, Clearmind is building a robust IP portfolio to support its clinical and commercial ambitions.
What we're watching
- Clinical Progress
- How the patent will accelerate Clearmind's clinical programs for binge-related disorders, particularly alcohol use disorder.
- IP Strategy
- Whether Clearmind can sustain its leadership in psychedelic-based therapies through continued IP expansion.
- Market Positioning
- The pace at which Clearmind can commercialize its lead candidate, CMND-100, and broader pipeline in major global markets.
Related topics